CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

JM Michot; R Bouabdallah; Jeanette Doorduijn; U Vitolo; MJ Kersten; A Chiappella; PL Zinzani; M Pourdehnad; Z Nikolova; V Ribrag

doi:10.1093/annonc/mdy048.006

CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

JM Michot, R Bouabdallah, Jeanette Doorduijn, U Vitolo, MJ Kersten, A Chiappella, PL Zinzani, M Pourdehnad, Z Nikolova, V Ribrag

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	iii9
Journal	Annals of Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy048.006
Publication status	Published - 2018

Research programs

EMC OR-01

Access to Document

10.1093/annonc/mdy048.006

http://hdl.handle.net/1765/128290

Cite this

Michot, JM., Bouabdallah, R., Doorduijn, J., Vitolo, U., Kersten, MJ., Chiappella, A., Zinzani, PL., Pourdehnad, M., Nikolova, Z., & Ribrag, V. (2018). CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL). Annals of Oncology, 29, iii9. https://doi.org/10.1093/annonc/mdy048.006

@article{22027189c4024e27849fe9d0e97a1d6a,

title = "CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)",

author = "JM Michot and R Bouabdallah and Jeanette Doorduijn and U Vitolo and MJ Kersten and A Chiappella and PL Zinzani and M Pourdehnad and Z Nikolova and V Ribrag",

year = "2018",

doi = "10.1093/annonc/mdy048.006",

language = "Undefined/Unknown",

volume = "29",

pages = "iii9",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

}

Michot, JM, Bouabdallah, R, Doorduijn, J, Vitolo, U, Kersten, MJ, Chiappella, A, Zinzani, PL, Pourdehnad, M, Nikolova, Z & Ribrag, V 2018, 'CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)', Annals of Oncology, vol. 29, pp. iii9. https://doi.org/10.1093/annonc/mdy048.006

TY - JOUR

T1 - CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

AU - Michot, JM

AU - Bouabdallah, R

AU - Doorduijn, Jeanette

AU - Vitolo, U

AU - Kersten, MJ

AU - Chiappella, A

AU - Zinzani, PL

AU - Pourdehnad, M

AU - Nikolova, Z

AU - Ribrag, V

PY - 2018

Y1 - 2018

U2 - 10.1093/annonc/mdy048.006

DO - 10.1093/annonc/mdy048.006

M3 - Article

SN - 0923-7534

VL - 29

SP - iii9

JO - Annals of Oncology

JF - Annals of Oncology

ER -